HassanBAlkhateebMD

PubMed

• The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.
  Marissa M Li, Anmol Baranwal, Mark Gurney, Syed Naseem Shah, Aref Al-Kali, Hassan B Alkhateeb, James M Foran, Cecilia Arana-Yi, Laura Ongie, Dong Chen, Abhishek A Mang...> ;Blood Advances. 2024 Apr 2
• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
  Isla M Johnson, Omer Karrar, Masooma Rana, Moazah Iftikhar, Sunny Chen, Kristen McCullough, Antoine N Saliba, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Mark Litzow...> ;British Journal of Haematology. 2024 Apr 1
• Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
  Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, Wi...> ;Haematologica. 2024 Mar 28
• Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
  Anmol Baranwal, Mark Gurney, Rami Basmaci, Bahga Katamesh, Rong He, David S Viswanatha, Patricia Greipp, James Foran, Talha Badar, Hemant Murthy, Cecilia Arana Yi, Jea...> ;Haematologica. 2024 Feb 1
• 12 citations
  Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive...
  Naseema Gangat, Omer Karrar, Moazah Iftikhar, Kristen McCullough, Isla M Johnson, Maymona Abdelmagid, Mostafa Abdallah, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begn...> ;American Journal of Hematology. 2024 Feb 1
• How do I manage refractory invasive pulmonary aspergillosis.
  Sendi, P., Nguyen, M., Vergidis, P., Alkhateeb, H.> ;Clinical Microbiology and Infection. 2024 Jan 28
• EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
  Anmol Baranwal, Abhishek Mangaonkar, Mithun V Shah, Aref Al-Kali, Ayalew Tefferi, William J Hogan, Mark R Litzow, Mrinal M Patnaik, Hassan B Alkhateeb> ;Bone Marrow Transplantation. 2024 Apr 1
• Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
  Gupta, S., Kohorst, M., Alkhateeb, H.> ;European Journal of Haematology. 2024 Jan 1
• 1 citations
  Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study.
  Herasevich, S., Schulte, P., Hogan, W., Alkhateeb, H., Zhang, Z., Khera, N., Roy, V., Gajic, O., Yadav, H., White, B., Zhang, Z.> ;American Journal of Respiratory and Critical Care Medicine. 2024 Mar 1
• Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms.
  Anmol Baranwal, Rong He, Hemant S Murthy, Mehrdad Hefazi, Aref Al-Kali, Hassan B Alkhateeb, Rami Basmaci, David Viswanatha, Patricia Greipp, James Foran, Jeanne Palmer...> ;Blood Advances. 2024 Feb 13
• 3 citations
  Mast cell cytomorphology and treatment outcome in mast cell leukemia.
  Ayalew Tefferi, Animesh Pardanani, Aref Al-Kali, Hassan Alkhateeb, Kristen McCullough, Mrinal Patnaik, William J Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera...> ;American Journal of Hematology. 2024 Jan 1
• U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
  Talha Badar, Yenny A Moreno Vanegas, Ahmad Nanaa, James M Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B Alkhateeb, David Viswanatha, Rong He, Mithu...> ;Blood Cancer Journal. 2023 Sep 21
• 5 citations
  Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
  Ahmad Nanaa, Rong He, James M Foran, Talha Badar, Naseema Gangat, Animesh Pardanani, William J Hogan, Mark R Litzow, Mrinal Patnaik, Aref Al-Kali, Hassan B Alkhateeb> ;British Journal of Haematology. 2024 Jan 1
• 1 citations
  Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arte...
  Maymona G Abdelmagid, Aref Al-Kali, Mark R Litzow, Kebede H Begna, William J Hogan, Mirinal S Patnaik, Shahrukh K Hashmi, Michelle A Elliott, Hassan Alkhateeb, Omer S ...> ;Blood Cancer Journal. 2023 Aug 11
• Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
  Naseema Gangat, Kristen McCullough, Maymona Abdelmagid, Omer Karrar, Marissa Powell, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek Mangaonkar, Antoine Saliba,...> ;Haematologica. 2024 Jan 1
• IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience.
  Naseema Gangat, Helen Ajufo, Maymona Abdelmagid, Omer Karrar, Kristen McCullough, Talha Badar, James Foran, Jeanne Palmer, Hassan Alkhateeb, Abhishek Mangaonkar, Andre...> ;British Journal of Haematology. 2023 Nov 1
• 2 citations
  Sodium-glucose co-transporter-2 inhibitor therapy and unmasking of JAK2-mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases.
  Naseema Gangat, Hassan Alkhateeb, Kaaren Reichard, Ayalew Tefferi> ;American Journal of Hematology. 2023 Oct 1
• 5 citations
  Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
  Ayalew Tefferi, Hassan Alkhateeb, Naseema Gangat> ;Blood Cancer Journal. 2023 Jul 18
• 1 citations
  Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
  Mark Gurney, Abhishek A Mangaonkar, Terra Lasho, Christy Finke, Aref Al-Kali, Naseema Gangat, Mithun V Shah, Hassan B Alkhateeb, Ayalew Tefferi, David Sallman, Zhuoer ...> ;Leukemia. 2023 Aug 1
• 1 citations
  Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
  Ji Yuan, Rong He, Hassan B Alkhateeb> ;Current Hematologic Malignancy Reports. 2023 Oct 1
• 3 citations
  Clinical and molecular correlates of somatic and germlinevariants in patients and families with myeloid neoplasms.
  Talha Badar, Ahmad Nanaa, James M Foran, David Viswanatha, Aref Al-Kali, Terra Lasho, Christy Finke, Hassan B Alkhateeb, Rong He, Naseema Gangat, Mithun Shah, Ayalew T...> ;Haematologica. 2023 Nov 1
• Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era.
  Talha Badar, Hassan Alkhateeb, Mahmoud Aljurf, Mohamed A Kharfan-Dabaja> ;Current Research in Translational Medicine. 2023 Apr 23
• 4 citations
  Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases.
  Naseema Gangat, Mostafa Abdallah, Natasha Szuber, Antoine Saliba, Hassan Alkhateeb, Aref Al-Kali, Kebede H Begna, Animesh Pardanani, Ayalew Tefferi> ;American Journal of Hematology. 2023 Jul 1
• 6 citations
  TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
  Mithun Vinod Shah, Elizabeth Ngoc Hoa Tran, Syed Shah, Rakchha Chhetri, Anmol Baranwal, Dariusz Ladon, Carl Shultz, Aref Al-Kali, Anna L Brown, Dong Chen, Hamish S Sco...> ;Blood Cancer Journal. 2023 Apr 11
• 3 citations
  Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome.
  Aref Al-Kali, Ahmad Nanaa, David Viswanatha, Rong He, Phuong Nguyen, Dragan Jevremovic, James M Foran, Cecelia Arana Yi, Patricia T Greipp, Naseema Gangat, Mrinal Patn...> ;Blood Cancer Journal. 2023 Apr 10
• Join now to see all

Journal Articles

• Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-Grade Myelodysplastic Syndromes  
  Hassan Alkhateeb, MD, Anticancer Research

Abstracts/Posters

• Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes
  Hassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
  Hassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial
  Hassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation
  Hassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...
  Hassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018